## JUN 1 8 2002 JUN 1 8 2002

## INFORMATION DISCLOSURE CITATION

OMB No. 0651-0011

RECEIVED

En				・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・
ARY MOBERET No.	04734.0005-00000	Appln. No.	10/073,203	JUN 1
Applicant	Hartmut STROBEL et al.			TECH OF 1 9 2002
Filing Date	February 13, 2002	Group:	1614	DENTER 1600/2000

U.S. PATENT DOCUMENTS						
Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS						
	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
B.K.	25 36 509	3/18/76	Germany			No
B.K.	WO 99/47153	9/23/99	PCT			
D.K.	*WO 00/03746	1/27/00	PCT	<u> </u>		
B.K.	WO 00/51970	9/8/00	PCT			

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
B.K.	Joseph G. Cannon et al., Comparison of Biological Effects of N-Alkylated Congeners of β-Phenethylamine Derived from 2-Aminotetralin, 2-Aminoindan, and 6-Aminobenzocyclohepten, J. Med. Chem., 1980, 23, 745-749					
B.K.	Matthias Endres et al., Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase, Proc. Natl. Acad. Sci. USA, July 1998, Vol. 95, pp. 8880-8885					
B·K.	Bansi Lal et al., Phenethylamine in a Rigid Framework. 2,3-Substituted <i>cis</i> - and <i>trans</i> -6-Amino-6,7,8,9-tetrahydro-5 <i>H</i> -benzocyclohepten-5-ols, Journal of Medicinal Chemistry, 1972, Vol. 15, No. 1, pp. 23-27					
B.K.	Phuige Li et al., Activation of Protein Kinase Cα and/or ε Enhances Transcription of the Human Endothelial Nitric Oxide Synthase Gene, Molecular Pharmacology (1998), 53:630-637					

Examiner	Brush XIL	Date Considered 5/22/03			
*Examiner:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				
Form PTO 14	49 Pa	atent and Trademark Office - U.S. Department of Commerce			

## **INFORMATION DISCLOSURE CITATION**

OMB No. 0651-0011

JUN 1 8 200	2 🕱 INFORMATI	INFORMATION DISCLOSURE CITATION		
9000	04734.0005-00000	Appln. No.	10/073,203	JUNICIVED
Applicant	Hartmut STROBEL et al.			TECH 0- 1 9 2002
Filing Date	February 13, 2002	Group:	1614	CENTER 1600/00
				2900

	U.S. PATENT DOCUMENTS					
Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	· · · · · · · · · · · · · · · · · · ·	FOREIGN PATE	NT DOCUMENTS	<u> </u>		
	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
	OTHER DOCUMEN	TS (Including Aut	thor, Title, Date, F	Pertinent F	Pages, Etc	:.)
B.K.	Masao Moroi et al., Interaction of Genetic Deficiency of Endothelial Nitric Oxide, Gender, and Pregnancy in Vascular Response to Injury in Mice, The Journal of Clinical Investigation, March, 1998, Vol. 101, No. 6, pp. 1225-1232					
B.K.	Masafumi Nakayama et al., T <sup>-786</sup> →C Mutation in the 5' -Flanking Region of the Endothelial Nitric Oxide Synthase Gene Is Associated With Coronary Spasm, Clinical Investigation and Reports (1999), 2864-2870					
D.K.	Günther Seidl et al., Die Reaktionen der 1.2-Benzo-cyclenyl-(4)-amine mit salpetriger Säure, Aus dem Institut für Organische Chemie der Universität München, Chem. Ber. 97 (1964), pp. 249-254					
B.K. B.K. B.K.	William C. Sessa et al., Chronic Exercise in Dogs Increases Coronary Vascular Nitric Oxide Production and Endothelial Cell Nitric Oxide Synthase Gene Expression, Circulation Research, 1994, Vol. 74, No. 2, 349-353					
B.K.	Olivier Varenne, et al., Percutaneous Gene Therapy Using Recombinant Adenoviruses Encoding Human Herpes Simplex Virus Thymidine Kinase, Human PAI-1, and Human NOS3 in Balloon-Injured Porcine Coronary Arteries, Human Gene Therapy (June 10, 2000) 11:1329-1339					
B.K.	Z.J. Vejdělek et al., 6-Amino-6,7,8,9-Tetrahydro-5 <i>H</i> -Benzocycloheptene and Derivatives, Collection Czechoslov. Chem. Commun., 1974, Vol. 39, pp. 2819-2827					

Examiner	Bunk XII	Date Considered 5/22/03				
*Examiner:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					
Form PTO 14	149	Patent and Trademark Office - U.S. Department of Commerce				